[go: up one dir, main page]

EA200801520A1 - CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13) - Google Patents

CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13)

Info

Publication number
EA200801520A1
EA200801520A1 EA200801520A EA200801520A EA200801520A1 EA 200801520 A1 EA200801520 A1 EA 200801520A1 EA 200801520 A EA200801520 A EA 200801520A EA 200801520 A EA200801520 A EA 200801520A EA 200801520 A1 EA200801520 A1 EA 200801520A1
Authority
EA
Eurasian Patent Office
Prior art keywords
human interleukin
chemical
antibodies against
humanized antibodies
against human
Prior art date
Application number
EA200801520A
Other languages
Russian (ru)
Inventor
Клэр Эшман
Мартин Джон Кэссиди
Джейн Элизабет Кларксон
Джонатан Генри Эллис
Тревор Энтони Кеннет Уоттэм
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200801520A1 publication Critical patent/EA200801520A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к иммуноглобулинам, в частности антителам, специфично связывающим человеческий интерлейкин-13 (hlL-13). Антитела по изобретению могут быть применены в лечении множества заболеваний или расстройств, чувствительных к модуляции взаимодействия между hlL-13 и рецептором человеческого IL-13. Такие заболевания включают тяжелую астму, атопический дерматит, хроническую обструктивную болезнь легких (ХОБЛ) и различные фиброзные заболевания. Также раскрыты фармацевтические композиции, содержащие указанные антитела, и способы их изготовления.The present invention relates to immunoglobulins, in particular antibodies specifically binding human interleukin-13 (hlL-13). The antibodies of the invention can be used in the treatment of a variety of diseases or disorders sensitive to the modulation of the interaction between hlL-13 and the receptor for human IL-13. Such diseases include severe asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD) and various fibrosis diseases. Also disclosed are pharmaceutical compositions containing these antibodies, and methods for their manufacture.

EA200801520A 2006-01-11 2007-01-10 CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13) EA200801520A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0600488.1A GB0600488D0 (en) 2006-01-11 2006-01-11 Immunoglobulins
PCT/EP2007/050219 WO2007080174A2 (en) 2006-01-11 2007-01-10 Chimeric and humanised anti-human il-13 antibodies

Publications (1)

Publication Number Publication Date
EA200801520A1 true EA200801520A1 (en) 2009-02-27

Family

ID=35997844

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801520A EA200801520A1 (en) 2006-01-11 2007-01-10 CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13)

Country Status (18)

Country Link
EP (1) EP1976881A2 (en)
JP (1) JP2009523154A (en)
KR (1) KR20080113201A (en)
CN (1) CN101370829A (en)
AR (1) AR058955A1 (en)
AU (1) AU2007204372A1 (en)
BR (1) BRPI0706481A2 (en)
CA (1) CA2635972A1 (en)
CR (1) CR10161A (en)
EA (1) EA200801520A1 (en)
GB (1) GB0600488D0 (en)
IL (1) IL192207A0 (en)
MA (1) MA30156B1 (en)
NO (1) NO20082767L (en)
PE (1) PE20081185A1 (en)
TW (1) TW200736274A (en)
WO (1) WO2007080174A2 (en)
ZA (1) ZA200805526B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5006330B2 (en) 2005-10-21 2012-08-22 ノバルティス アーゲー Human antibodies against IL13 and therapeutic uses
ES2514495T3 (en) 2006-05-25 2014-10-28 Glaxo Group Limited Humanized anti-interleukin-18 modified antibodies
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
BRPI0823231A2 (en) * 2008-11-26 2015-06-16 Glaxo Group Ltd Single variable domain of anti-interleukin-13 (il-13) immunoglobulin, interleukin-13 (il-13) antagonist, use of antagonist, method for treating and / or preventing an il-13-mediated condition in a patient, device Dispensing device containing the antagonist, double specific ligand, isolated or recombinant nucleic acid, vector, host cell, method for producing polypeptide, and fusion protein.
KR101579771B1 (en) 2009-03-05 2015-12-28 애브비 인코포레이티드 IL-17 binding proteins
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
TW201107345A (en) * 2009-05-28 2011-03-01 Glaxo Group Ltd Immunoglobulins
RU2603055C2 (en) 2009-10-20 2016-11-20 Эббви Инк Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
PL2627673T3 (en) * 2010-10-15 2018-01-31 Medimmune Ltd Therapies for improving pulmonary function
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
TWI700093B (en) 2011-03-16 2020-08-01 法商賽諾菲公司 Uses of a dual v region antibody-like protein
CA2924873A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
WO2015127405A2 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
AU2015246037B2 (en) 2014-04-11 2018-04-12 Novartis Ag Methods of selectively treating asthma using IL-13 antagonists
JP2018511797A (en) 2015-03-16 2018-04-26 ジェネンテック， インコーポレイテッド IL-13 detection and quantification method and use in diagnosis and treatment of Th2-related diseases
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
PL3448391T3 (en) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2018135653A1 (en) * 2017-01-23 2018-07-26 学校法人東洋大学 Anti-epha2 antibody and immunological detection of epha2 using same
CN109776677B (en) * 2017-11-15 2023-11-03 尚华科创投资管理（江苏）有限公司 Humanized anti-IL-13 antibody and preparation method and application thereof
CN107909501B (en) * 2017-12-05 2020-12-01 创新先进技术有限公司 Correlation method of smell and behavior, smell socialization method and device
JP7418337B2 (en) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド Treatment and diagnosis of mast cell-mediated inflammatory diseases
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US20240317892A1 (en) * 2019-03-20 2024-09-26 Javelin Oncology, Inc Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503018A (en) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド vaccine
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
ES2775204T3 (en) * 2003-12-23 2020-07-24 Genentech Inc Novel anti-IL13 antibodies and uses thereof
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
GB0600488D0 (en) 2006-02-22
MA30156B1 (en) 2009-01-02
WO2007080174A3 (en) 2007-12-06
BRPI0706481A2 (en) 2011-03-29
CN101370829A (en) 2009-02-18
NO20082767L (en) 2008-10-06
WO2007080174A2 (en) 2007-07-19
PE20081185A1 (en) 2008-10-07
EP1976881A2 (en) 2008-10-08
JP2009523154A (en) 2009-06-18
CA2635972A1 (en) 2007-07-19
CR10161A (en) 2008-11-26
AR058955A1 (en) 2008-03-05
AU2007204372A1 (en) 2007-07-19
ZA200805526B (en) 2009-10-28
IL192207A0 (en) 2008-12-29
TW200736274A (en) 2007-10-01
KR20080113201A (en) 2008-12-29

Similar Documents

Publication Publication Date Title
EA200801520A1 (en) CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13)
SG153878A1 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
WO2009052081A3 (en) Antibodies that bind il-4 and/or il-13 and their uses
CY1120874T1 (en) INTERLEUKIN ANTIBODY SYNTHESIS-13
WO2009074634A3 (en) Polypeptides, antibody variable domains & antagonists
MX340696B (en) Anti-c5a antibodies and methods for using the antibodies.
WO2007045477A3 (en) Human antibodies against il-13 and therapeutic uses
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
MX2009010765A (en) Anti-ige antibodies.
UA95478C2 (en) Humanized c-kit antibody
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
EA201290849A1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI)
UA100377C2 (en) Antibodies against il-25
WO2010038155A3 (en) Antibodies against il-25
WO2007003421A3 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
TH83335A (en) Immunoglobulin
TH97785A (en) Immunoglobulin
TW200610768A (en) IL-13 binding antibodies